1.Autoradiography observation on cochlea and organs in guinea pigs after intra-abdominal injection of bFGF.
Suoqiang ZHAI ; Panzao CHEN ; Wei GUO ; Ning YU ; Jainhe SUN ; Yinyan HU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2010;24(16):750-752
OBJECTIVE:
To observe whether bFGF could cross the blood-labyrinth barrier (BLB) after intra-abdominal injection and to establish an experimental basis for its clinical applications.
METHOD:
Thirty guinea pigs were divided into three groups. Animals in group 1 were administered o I-bFGF, while animals in group 2 and 3 were administered 125 and saline, respectively, via intra-abdominal injection. The both cochlea, blood, liver, brain, thyroid gland and kidney were collected and weighted. A radioimmunoassay analyzer was employed to measure counts per minute (CPM) of each sample, and autoradiography was performed on both cochlea.
RESULT:
The CPM value of organ samples in the 125I group was higher than that in other groups, and radioactive grain was observed in cochlear samples of this group. In the 125I-bFGF group, blood demonstrated the highest CPM value, while cochlea and brain demonstrated the lowest CPM value, with no radioactive grain observed in cochlear samples.
CONCLUSION
bFGF has some difficulties in getting across BLB, so the way of bFGF application in clinics need further study.
Animals
;
Autoradiography
;
Cochlea
;
cytology
;
metabolism
;
Fibroblast Growth Factor 2
;
administration & dosage
;
Guinea Pigs
;
Injections, Intraperitoneal
;
Iodine Radioisotopes
;
administration & dosage
2.Distribution of basic fibroblast growth factor in inner ear of guinea pigs injected by different drug-approaches.
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2005;40(2):115-118
OBJECTIVETo investigate the approach of basic fibroblast growth factor(bFGF) entering inner ear, as well as its the protective mechanism to inner ear and nerve tissue in pathological situation.
METHODS125I-bFGF was injected into guinea pigs body via the lateral ventricle and muscle under physical situation as well as pathological situation. Then the per minute gamma-radioactive in blood, liver, thyroid gland, brain, cochlear and perilymph fluid was counted, and the distribution and metabolism of bFGF in the inner ear and autoradiography of the cochlea were also observed.
RESULTSGamma-radioactive cpm of blood and liver increased significantly, while it did not change in brain, cochlea and perilymph after 125I-bFGF intramuscular injections. Gamma-radioactive cpm in blood, liver, brain, perilymph and cochlea had increased and autoradiography granules was found in the cochlea in 30 min after 125I-bFGF injected into CSF. In brain, perilymph and cochlea, a maximal value of gamma-radioactive cpm was obtained between 2 h and 4 h, while that in 8 h decreased significantly. Autoradiography granules still were seen in 8 h. gamma-radioactive cpm in 12 h was still higher than that in control group, but autoradiography granules can't be seen. The result in 24 h was similar to that in control group. The time course of cpm in the blood, cochlea and perilymph always parallel changed.
CONCLUSIONSbFGF has some difficulties in getting across blood-labyrinth barrier (BLB) and blood-brain barrier (BBB) under physical and pathological situation, such as acute anoxia, aminoglycoside-induced deafness. bFGF can reach inner ear, perilymph fluid, brain tissue and blood rapidly when it is injected into CSF and excreted slowly in those tissues. Permeability of BBB and BLB to bFGF is similar and has orientation.
Animals ; Autoradiography ; Blood-Brain Barrier ; metabolism ; Ear, Inner ; metabolism ; Fibroblast Growth Factor 2 ; administration & dosage ; pharmacokinetics ; Guinea Pigs ; Iodine Radioisotopes ; administration & dosage
3.Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma.
Journal of Biomedical Engineering 2012;29(3):588-592
Traditionally, during the follow-up and in order to receive 131 I therapy, patients with differentiated thyroid carcinoma (DTC) have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life (QOL) of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hormone (rhTSH) in the management of DTC patients.
Humans
;
Iodine Radioisotopes
;
therapeutic use
;
Thyroglobulin
;
blood
;
Thyroid Hormones
;
administration & dosage
;
Thyroid Neoplasms
;
blood
;
drug therapy
;
radiotherapy
;
Thyrotropin Alfa
;
administration & dosage
4.Mechanism of cardiotoxicity associated with Herceptin using (131)I-Herceptin radioimmunoimaging.
Yi-xiang FAN ; Rong-cheng LUO ; Mei-ju GAO ; Qing-zhu LIU ; Ke-bin LI ; Ji-zhen WU ; Wei-min SHI
Journal of Southern Medical University 2009;29(12):2477-2484
OBJECTIVETo study the mechanism of cardiotoxicity associated with Herceptin.
METHODSHerceptin was labeled with iodine-131 using the Iodogen method. Radioimmunoimaging was performed in 5 rabbits at 3 h to 5 days following (131)I-Herceptin injection to investigate the biodistribution of Herceptin. (131)I-Herceptin uptake in each organ or tissue relative to that in the muscular tissue (O/M ratio) was calculated and compared. On the fifth day following the injection, the organs including the heart, lung, liver and muscles were taken for measurement of the weight and radiocounts. HER2 expression was measured by immunohistochemistry in these organs and tissues.
RESULTSThe O/M ratio of the heart was significantly higher than that of the lung (P=0.032) and liver (P=0.019) at 3 h after Herceptin injection, but reduced significantly at 24 h (P=0.001). The uptake of (131)I-Herceptin in the myocardium was slightly higher that that in the muscle and intestine, but lower than that in the lung and spleen. HER2 expression showed no significant difference between the myocardium and the other tissues such as the liver, lung, and kidney (H=3.236, P=0.172).
CONCLUSIONMyocardium expresses low levels of HER2 and accumulates Herceptin no more than the other tissues.
Animals ; Antibodies, Monoclonal ; administration & dosage ; pharmacokinetics ; toxicity ; Antibodies, Monoclonal, Humanized ; Female ; Iodine Radioisotopes ; administration & dosage ; pharmacokinetics ; Male ; Myocardium ; metabolism ; Rabbits ; Radioimmunodetection ; Receptor, ErbB-2 ; metabolism ; Tissue Distribution ; Trastuzumab
5.The technic and dose evaluation of postoperative (125)I radioactive seeds brachytherapy for malignant tumors of maxilla.
Ming-wei HUANG ; Dai TONG ; Jie ZHANG ; Hong-zhi ZHANG ; Jian-guo ZHANG ; Guang-yan YU
Chinese Journal of Stomatology 2009;44(9):517-519
OBJECTIVETo evaluate the technique and effect of treating malignant tumors of maxilla with postoperative brachytherapy by digital model obturators containing (125)I radioactive seeds.
METHODSFour patients with adnoid cystic carcinomas and two with squamous cell carcinomas in the maxilla were included in this study. All patients accepted (125)I seeds implantation after operation, and wore digital model obturators containing (125)I seeds. The prescription dose was 80 Gy. All patients were followed up every 2 months after treatment.
RESULTSThe total number of seeds used in these six patients was 189, and 105 seeds were contained in obturators. Radioactive seeds and doses distributed very well as designed in all patients. No tumors recurred after follow up of 12-16 months and there were no severe complications.
CONCLUSIONSIt's an effective way to treat malignant tumors with positive excision margin in the maxilla by brachytherapy using digital model obturators which contain (125)I radioactive seeds.
Adult ; Aged ; Brachytherapy ; methods ; Carcinoma, Adenoid Cystic ; radiotherapy ; Carcinoma, Squamous Cell ; radiotherapy ; Female ; Humans ; Iodine Radioisotopes ; administration & dosage ; therapeutic use ; Male ; Maxillary Neoplasms ; radiotherapy ; Middle Aged ; Young Adult
6.Combination of transrectal 125I seeds implantation brachytherapy and intermittent hormonal therapy for locally advanced prostate cancer.
Hao-Ming WU ; Jun LÜ ; Wei-Lie HU ; Jin-He ZHANG ; Wei WANG ; Yuan-Song XIAO ; Nan-Xiong WANG ; Jun-Wu RAN ; Xiao-Dong HUANG
National Journal of Andrology 2013;19(7):617-621
OBJECTIVETo evaluate the clinical efficacy of transrectal 125 I seeds implantation brachytherapy (BT) combined with intermittent hormonal therapy (IHT) in the treatment of locally advanced prostate cancer.
METHODSWe treated 27 patients with locally advanced prostate cancer by transrectal 125I seeds implantation BT combined with IHT, and dynamically observed the changes in the PSA level, prostate volume, maximum urinary flow rate (Qmax) and International Prostate Symptoms Score (IPSS).
RESULTSAll the implantation procedures were completed smoothly, lasting 20 to 35 minutes, with 40 to 58 seeds implanted. At 6 months after implantation, the PSA level was < 0.2 microg/L in all the patients (< 0.1 microg/L in 19 cases), the prostate volume was significantly reduced (P < 0.05), and Qmax and IPSS remarkably improved (P < 0.05). At 3 years after implantation, 19 cases were in the first cycle and the other 8 in the third cycle of IHT, of which 2 progressed to androgen-independent prostate cancer, and another 2 developed early bone metastasis. The rates of 3-year biochemically and clinically progression-free survival were 70.3% and 85.2%, respectively, and the rate of therapeutic effectiveness was 92.6%. No severe complications occurred in any of the cases.
CONCLUSIONTransrectal 125I seeds implantation BT combined with IHT is a safe and minimally invasive procedure for locally advanced prostate cancer, which can effectively retard its clinical progression with no such complications as severe urethral, rectal or erectile dysfunction.
Aged ; Brachytherapy ; Combined Modality Therapy ; Hormones ; therapeutic use ; Humans ; Iodine Radioisotopes ; administration & dosage ; therapeutic use ; Male ; Prostatic Neoplasms ; radiotherapy ; therapy ; Treatment Outcome
8.Preliminary study of treating parotid gland malignant tumor with saving facial nerve (surgery associated with 125I seed implant brachytherapy).
Jian-guo ZHANF ; Jie ZHANG ; Tie-li SONG ; Lei ZHENG ; Zhi-gang CAI ; Guang-yan YU
Chinese Journal of Stomatology 2008;43(3):132-135
OBJECTIVETo study the clinical effect of treating parotid gland malignant tumor with facial never-preserving surgery combined with 125I seed implant brachytherapy.
METHODSThirty-two patients with parotid gland malignancy underwent tumor and parotid gland excision while preserving facial never. According to treating plan system (TPS), 125I seeds were implanted into the target area during or after operation. The patients were followed up after operation and the local tumor control and facial nerve function were observed.
RESULTSTumor recurrence was not found in any patient treated after 12 to 44 months of follow up. All patients did not show obvious radiation-related complications. The facial never function of all patients was basically normal 6 months after operation.
CONCLUSIONSFor parotid gland malignant tumor, surgery combined with 125I seeds implant brachytherapy can save facial nerve function, and the short-term effects were satisfactory.
Adolescent ; Adult ; Aged ; Brachytherapy ; Facial Nerve ; pathology ; Female ; Humans ; Iodine Radioisotopes ; administration & dosage ; therapeutic use ; Male ; Middle Aged ; Parotid Neoplasms ; pathology ; radiotherapy ; Treatment Outcome ; Young Adult
9.Ultrastructural study on the facial nerve of rabbit after (125)I seed implantation.
Jian ZUO ; Tie-li SONG ; Xiang-qun JU ; Lei ZHENG ; Zhi-gang CAI ; Jian-guo ZHANG
Chinese Journal of Stomatology 2011;46(8):498-501
OBJECTIVETo investigate the ultrastructural variation of the facial nerve of rabbit with different dosage of (125)I seed brachytherapy.
METHODSFifty-four big ear rabbits were divided into 3 groups randomly and given 40 Gy, 80 Gy, 120 Gy respectively. Radioactive seeds were implanted in one side of parotid gland, the other side was implanted with vacant shell as a control group. The facial nerves were obtained 2, 4, 6 months respectively after operation and the histological ultrastructural changes observed by electromicroscope.
RESULTSIn the control group, epineurium was continuous, there was slight pitting edema under the epineurium, and axonal myelin was loose. In the test groups, there was slight pitting edema under the epineurium, and axonal myelin sheath was loose at 4th month. Macrophage and regenerated fibers were found in the 80 Gy group and myelin sheath lamellar separation, regeneration of nerve in the 120 Gy dosage. The myelin sheath lamellar was separated and axonal myelin loose in the test group at 6th month. Myelin sheath amellar separation and edema under the epineurium were found in the group of 80 Gy and 120 Gy.
CONCLUSIONSThe ultrastructure of the facial nerve is damaged by the dosage of 40 Gy, 80 Gy brachytherapy with (125)I seeds. The higher dosage the nerve receives, the more serious the damage will be. Both of the epineurium and axonal myelin sheath are integral and continuous 6 months after operation with dosage of 120 Gy.
Animals ; Brachytherapy ; Dose-Response Relationship, Radiation ; Facial Nerve ; radiation effects ; ultrastructure ; Female ; Iodine Radioisotopes ; administration & dosage ; radiation effects ; Male ; Rabbits ; Radiation Injuries, Experimental ; pathology ; Random Allocation
10.Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma.
Wusheng LU ; Xiao LI ; Chaohua WANG ; Wenxiu LIU ; He JIAO ; Tingshu MO ; Zhinan CHEN
Journal of Biomedical Engineering 2003;20(4):689-691
Before 131I-HAb18F(ab')2 administration, 24 cases of mid-term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging. The cases were randomly divided into 3 groups. Then 131I-HAb18F(ab')2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48, 96 and 192 hours, 131I-HAb18F(ab')2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131I-HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131I-HAb18F(ab')2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.
Adult
;
Aged
;
Antibodies, Monoclonal
;
administration & dosage
;
pharmacokinetics
;
Carcinoma, Hepatocellular
;
radiotherapy
;
Female
;
Humans
;
Immunoglobulin Fab Fragments
;
administration & dosage
;
metabolism
;
Iodine Radioisotopes
;
administration & dosage
;
pharmacokinetics
;
Liver Neoplasms
;
radiotherapy
;
Male
;
Middle Aged
;
Radioimmunotherapy
;
Radiopharmaceuticals
;
administration & dosage
;
pharmacokinetics
;
Tissue Distribution